Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cornerstone Therapeutics Inc. (“Cornerstone” or the “Company”) (Nasdaq: CRTX) related to the proposed acquisition of the Company by Chiesi Farmaceutici S.p.A. (“Chiesi”). Under the terms of the agreement, Chiesi will acquire all of the outstanding common stock of Cornerstone that it does not already own for a cash purchase price of between $6.40 and $6.70 per share.
The investigation concerns whether the Cornerstone Board of Directors is violating its fiduciary duties and whether the proposed per share consideration adequately values Cornerstone common shares.
If you are a Cornerstone shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.Business Wire
Last updated on: 26/02/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.